LU93312I2 - Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate - Google Patents

Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate Download PDF

Info

Publication number
LU93312I2
LU93312I2 LU93312C LU93312C LU93312I2 LU 93312 I2 LU93312 I2 LU 93312I2 LU 93312 C LU93312 C LU 93312C LU 93312 C LU93312 C LU 93312C LU 93312 I2 LU93312 I2 LU 93312I2
Authority
LU
Luxembourg
Prior art keywords
salt
migalastat
chlorhydrate
including salt
Prior art date
Application number
LU93312C
Other languages
English (en)
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38723987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU93312(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of LU93312I2 publication Critical patent/LU93312I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/94—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Ecology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU93312C 2006-05-16 2016-11-16 Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate LU93312I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80108906P 2006-05-16 2006-05-16
US85363106P 2006-10-23 2006-10-23
PCT/US2007/069046 WO2007137072A2 (fr) 2006-05-16 2007-05-16 Dosages biologiques pour le diagnostic et l'évaluation d'options de traitement de la maladie de fabry

Publications (1)

Publication Number Publication Date
LU93312I2 true LU93312I2 (fr) 2017-01-26

Family

ID=38723987

Family Applications (1)

Application Number Title Priority Date Filing Date
LU93312C LU93312I2 (fr) 2006-05-16 2016-11-16 Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate

Country Status (19)

Country Link
US (9) US7851143B2 (fr)
EP (6) EP2533050B3 (fr)
JP (7) JP2009537149A (fr)
AU (1) AU2007253900A1 (fr)
CA (1) CA2652553C (fr)
CY (3) CY1115180T1 (fr)
DK (3) DK2533050T6 (fr)
ES (4) ES2464527T7 (fr)
FI (1) FI3457135T3 (fr)
HK (1) HK1218955A1 (fr)
HU (3) HUE071237T2 (fr)
LT (2) LT3457135T (fr)
LU (1) LU93312I2 (fr)
MX (2) MX351004B (fr)
NL (1) NL300843I2 (fr)
PL (3) PL2787345T3 (fr)
PT (2) PT3457135T (fr)
SI (3) SI3457135T1 (fr)
WO (1) WO2007137072A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2533050B3 (fr) 2006-05-16 2015-06-24 Amicus Therapeutics, Inc. Options de traitement pour la maladie de Fabry
MX2009011473A (es) * 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
SI2252313T1 (sl) 2008-02-12 2015-08-31 Amicus Therapeutics, Inc. Postopek napovedovanja odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
MX2010009875A (es) * 2008-03-12 2010-11-26 Amicus Therapeutics Inc Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de pompe.
EP2502068B1 (fr) * 2009-11-17 2016-02-10 Baylor Research Institute Triaosylceramide urinaire (gb3) comme marqueur de maladie cardiaque
AU2011223706A1 (en) * 2010-03-05 2012-09-20 Baylor Research Institute Involvement of androgen/androgen receptor pathway in Fabry disease
CN107088225A (zh) * 2011-03-11 2017-08-25 阿米库斯治疗学公司 治疗法布里病的给药方案
WO2012154967A1 (fr) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Régulateurs de la protéostasie
BR112014014808A2 (pt) * 2011-12-22 2018-09-25 Centogene Ip Gmbh combinações de um composto que tem a capacidade de reorganizar uma enzima lisossômica e ambroxol e/ou um derivado de ambroxol, sua utilização, preparação farmacêutica e seu método de preparação
EP2806875B1 (fr) 2012-01-25 2017-07-19 Proteostasis Therapeutics, Inc. Composés permettant de moduler l'activité de protéasome
WO2014127038A1 (fr) * 2013-02-12 2014-08-21 Baylor Research Institute Procédés et compositions associés à l'homéostase du calcium et la maladie de fabry
ES2732308T3 (es) * 2013-12-23 2019-11-21 Bcn Peptides Sa Análogos de bicalutamida o (s)-bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis
US9675627B2 (en) * 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
ES2715889T3 (es) 2014-07-25 2019-06-06 Shire Human Genetic Therapies Estructura cristalina del dominio de tipo proteína de transferencia de glicolípidos de la proteína adaptadora de cuatro fosfatos 2 humana
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CA3031249A1 (fr) * 2016-07-19 2018-01-25 Amicus Therapeutics, Inc. Traitement de la maladie de fabry chez des patients soumis a une therapie enzymatique substitutive (ert) et chez des patients non soumis a une ert
US12020820B1 (en) 2017-03-03 2024-06-25 Cerner Innovation, Inc. Predicting sphingolipidoses (fabry's disease) and decision support
US11335461B1 (en) 2017-03-06 2022-05-17 Cerner Innovation, Inc. Predicting glycogen storage diseases (Pompe disease) and decision support
KR102631805B1 (ko) 2017-05-30 2024-01-31 아미쿠스 세라퓨틱스, 인코포레이티드 신장 손상을 갖는 파브리 환자를 치료하는 방법
EP3630114B1 (fr) * 2017-05-30 2023-11-01 Amicus Therapeutics, Inc. Migalastat pour le traitement de patients atteints de la maladie de fabry souffrants d'une insuffisance rénale
US11923048B1 (en) 2017-10-03 2024-03-05 Cerner Innovation, Inc. Determining mucopolysaccharidoses and decision support tool
JP7555818B2 (ja) 2018-02-06 2024-09-25 アミカス セラピューティックス インコーポレイテッド 妊娠患者におけるファブリー病の治療のためのミガラスタットの使用
HUE064761T2 (hu) * 2018-02-06 2024-04-28 Amicus Therapeutics Inc Klasszikus FABRY-betegségben szenvedõ betegek kezelése migalasztáttal
WO2020006269A1 (fr) 2018-06-27 2020-01-02 Proteostasis Therapeutics, Inc. Composés améliorant l'activité du protéasome
MX2020014082A (es) 2018-06-27 2021-04-13 Proteostasis Therapeutics Inc Compuestos que mejoran la actividad del proteasoma.
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
HRP20260109T1 (hr) 2019-08-07 2026-03-13 Amicus Therapeutics, Inc. Migalastat za upotrebu u liječenju fabryjeve bolesti kod pacijenata koji imaju mutaciju u gla genu
US11191827B1 (en) 2020-12-09 2021-12-07 Tevogen Bio Inc. COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463109A4 (en) * 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
WO1992000277A1 (fr) * 1990-06-29 1992-01-09 Nippon Shinyaku Co., Ltd. Derive de piperidine
EP0959877A4 (fr) 1996-04-10 2000-08-23 Univ California Correction des defaillances genetiques a l'aide de chaperons chimiques
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US7842470B2 (en) 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
CN102586205A (zh) 2003-01-31 2012-07-18 纽约大学西奈山医学院 酶和酶的活性部位特异性陪伴分子的组合
US7446098B2 (en) * 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
US20070066543A1 (en) * 2003-05-22 2007-03-22 The Hospital For Sick Children Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
BRPI0416216A (pt) 2003-11-12 2006-12-26 Amicus Therapeutics Inc composto de glicoimidazol e polihidroxiciclohexenila e método para sintetizar composto de glicoimidazol e polihidroxiciclohexenila, métodos para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir uma -glicosidade, e para tratar doença de gaucher, derivado de glicoimidazol e derivados de polihidroxiciclohexilamina
EP3782655A1 (fr) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. Procédé pour le traitement de la maladie de pompe au moyen de 1-désoxynojirimycine et de ses dérivés
WO2008045015A1 (fr) 2005-06-08 2008-04-17 Amicus Therapeutics, Inc. Purification d'imino- et amino-sucre
WO2006133446A2 (fr) 2005-06-08 2006-12-14 Amicus Therapeutics, Inc. Traitement de troubles du snc associes a des mutations dans des genes codant pour des enzymes lysosomales
AU2006272497B2 (en) 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
WO2007089591A2 (fr) 2006-01-27 2007-08-09 The Board Of Trustees Of The Leland Stanford Junior University Compositions et méthodes pour criblage à haut débit de chaperons pharmacologiques
EP2533050B3 (fr) 2006-05-16 2015-06-24 Amicus Therapeutics, Inc. Options de traitement pour la maladie de Fabry
DE602007012924D1 (de) 2006-09-22 2011-04-14 Krka Tovarna Zdravil D D Aripiprazolhemifumarat und verfahren zu dessen herstellung
CA2682441A1 (fr) 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Procede pour le traitement de la maladie de fabry utilisant des chaperons pharmacologiques
MX2009011473A (es) 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
SI2252313T1 (sl) 2008-02-12 2015-08-31 Amicus Therapeutics, Inc. Postopek napovedovanja odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
WO2010048532A1 (fr) 2008-10-24 2010-04-29 Amicus Therapeutics, Inc. Modèle de dosage à multiples compartiments
US9206457B2 (en) 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
JP5805630B2 (ja) 2009-05-26 2015-11-04 アミカス セラピューティックス インコーポレイテッド 生物製剤の製造および精製を改善するための薬理学的シャペロンの利用
EP2502068B1 (fr) 2009-11-17 2016-02-10 Baylor Research Institute Triaosylceramide urinaire (gb3) comme marqueur de maladie cardiaque
CN107088225A (zh) 2011-03-11 2017-08-25 阿米库斯治疗学公司 治疗法布里病的给药方案
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
EP2874648A4 (fr) 2012-07-17 2015-12-30 Amicus Therapeutics Inc Co-formulation d'alpha-galactosidase a et de 1-désoxygalactonojirimycine
JP7098529B2 (ja) 2016-03-22 2022-07-11 アミカス セラピューティックス インコーポレイテッド Ｇｌａ遺伝子にｇ９３３１ａ変異を有する患者においてファブリー病を処置する方法
CA3031249A1 (fr) 2016-07-19 2018-01-25 Amicus Therapeutics, Inc. Traitement de la maladie de fabry chez des patients soumis a une therapie enzymatique substitutive (ert) et chez des patients non soumis a une ert
US11357834B2 (en) 2017-01-10 2022-06-14 Amicus Therapeutics, Inc. Recombinant α-galactosidase A for treatment of Fabry disease
KR102631805B1 (ko) 2017-05-30 2024-01-31 아미쿠스 세라퓨틱스, 인코포레이티드 신장 손상을 갖는 파브리 환자를 치료하는 방법
SG11202000423XA (en) 2017-07-19 2020-02-27 Amicus Therapeutics Inc Treatment of fabry disease in ert-naïve and ert-experienced patients
SMT202200459T1 (it) 2017-08-28 2023-01-13 Amicus Therapeutics Inc Metodi di potenziamento e/o stabilizzazione della funzione cardiaca in pazienti con malattia di fabry
JP7555818B2 (ja) 2018-02-06 2024-09-25 アミカス セラピューティックス インコーポレイテッド 妊娠患者におけるファブリー病の治療のためのミガラスタットの使用
HUE064761T2 (hu) 2018-02-06 2024-04-28 Amicus Therapeutics Inc Klasszikus FABRY-betegségben szenvedõ betegek kezelése migalasztáttal
US20210315875A1 (en) 2018-08-20 2021-10-14 Amicus Therapeutics, Inc. Methods of Treating Fabry Disease in Patients Having a Mutation in the GLA Gene
US20220313670A1 (en) 2019-06-11 2022-10-06 Amicus Therapeutics, Inc. Methods Of Treating Fabry Disease In Patients Having Renal Impairment
HRP20260109T1 (hr) 2019-08-07 2026-03-13 Amicus Therapeutics, Inc. Migalastat za upotrebu u liječenju fabryjeve bolesti kod pacijenata koji imaju mutaciju u gla genu

Also Published As

Publication number Publication date
DK2787345T3 (en) 2016-05-30
EP4541418A3 (fr) 2025-07-09
EP2024745A4 (fr) 2010-03-17
EP2955520B1 (fr) 2018-10-31
FI3457135T3 (fi) 2025-03-08
JP2023027053A (ja) 2023-03-01
MX2008014679A (es) 2009-04-14
CA2652553C (fr) 2020-08-18
EP2533050B1 (fr) 2014-03-12
US20190388409A1 (en) 2019-12-26
EP2787345A1 (fr) 2014-10-08
US9480682B2 (en) 2016-11-01
DK2533050T3 (da) 2014-06-02
EP2533050A1 (fr) 2012-12-12
EP2533050B3 (fr) 2015-06-24
ES2464527T3 (es) 2014-06-03
EP4541418A2 (fr) 2025-04-23
US10383864B2 (en) 2019-08-20
US20150238474A1 (en) 2015-08-27
AU2007253900A1 (en) 2007-11-29
SI3457135T1 (sl) 2025-07-31
CY1117656T1 (el) 2017-05-17
PT2533050E (pt) 2014-05-26
MX351004B (es) 2017-09-26
NL300843I2 (fr) 2016-12-21
ES2573498T3 (es) 2016-06-08
SI2533050T1 (sl) 2014-07-31
HK1218955A1 (en) 2017-03-17
LT3457135T (lt) 2025-05-12
JP7175297B2 (ja) 2022-11-18
HUE027569T2 (en) 2016-10-28
LTPA2016033I1 (lt) 2016-12-12
CA2652553A1 (fr) 2007-11-29
JP2020196717A (ja) 2020-12-10
US9987263B2 (en) 2018-06-05
PL3457135T3 (pl) 2025-06-09
WO2007137072A2 (fr) 2007-11-29
HK1129458A1 (en) 2009-11-27
PT3457135T (pt) 2025-02-04
US20170042868A1 (en) 2017-02-16
ES2464527T7 (es) 2015-09-14
ES2709445T3 (es) 2019-04-16
EP3457135B1 (fr) 2024-12-04
PL2787345T3 (pl) 2016-08-31
JP2025060691A (ja) 2025-04-10
PL2533050T6 (pl) 2016-05-31
WO2007137072A3 (fr) 2008-10-16
PL2533050T3 (pl) 2014-08-29
US20120220632A1 (en) 2012-08-30
US20080056994A1 (en) 2008-03-06
JP6800176B2 (ja) 2020-12-16
JP6026268B2 (ja) 2016-11-16
JP2018138564A (ja) 2018-09-06
EP2787345B1 (fr) 2016-02-24
EP2787345B8 (fr) 2016-04-13
JP2013100307A (ja) 2013-05-23
US9000011B2 (en) 2015-04-07
US20220160690A1 (en) 2022-05-26
HK1178975A1 (en) 2013-09-19
LTC2787345I2 (lt) 2017-10-10
DK2533050T6 (da) 2015-09-21
US20180325881A1 (en) 2018-11-15
US20180250279A1 (en) 2018-09-06
JP2009537149A (ja) 2009-10-29
JP2016006088A (ja) 2016-01-14
US11241422B2 (en) 2022-02-08
DK3457135T3 (da) 2025-02-24
EP2024745A2 (fr) 2009-02-18
US10406143B2 (en) 2019-09-10
HUE071237T2 (hu) 2025-08-28
CY1115180T1 (el) 2016-12-14
HUS1600048I1 (hu) 2017-01-30
US7851143B2 (en) 2010-12-14
EP3457135A1 (fr) 2019-03-20
EP2024745B1 (fr) 2015-07-08
SI2787345T1 (sl) 2016-08-31
ES3012794T3 (en) 2025-04-10
CY2016040I1 (el) 2017-06-28
CY2016040I2 (el) 2017-06-28
EP2955520A1 (fr) 2015-12-16
ES2464527T9 (es) 2015-07-24
US20110104727A1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
LU93312I2 (fr) Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate
LU92568I2 (fr) Siméprévir, ou un sel de celui-ci, y compris le sodium siméprévir
LU93327I2 (fr) Opicapone ou un sel pharmaceutiquement acceptable de celui-ci
LU92672I2 (fr) Fluralaner ou un de ses sels
EP2298747A4 (fr) Dérivé de triazole ou sel de celui-ci
LU92864I2 (fr) Cobicistat ou un de ses sels pharmaceutiquement acceptables
LU92785I2 (fr) Céritinib ou un sel pharamceutiquement acceptable de celui-ci
BRPI0815588A2 (pt) Compostos de poliorganossiloxano-poliuréia e/ou de poliorganossilo-xano-poliuretano
LU92446I2 (fr) Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium
EP2042480A4 (fr) Dérivé d'aminoindane ou sel de celui-ci
EP2540716A4 (fr) Dérivé tétrazolyloxime ou un sel de celui-ci, et germicide
EP2149561A4 (fr) Dérivé de tétrahydroisoquinolin-1-one ou sel de celui-ci
BRPI0720547A2 (pt) Inibidores de metaloprotease derivada de heterocíclico
EP2110789A4 (fr) Processeur de papier-monnaie
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
DE602006009921D1 (de) Pigmentierter keramischer Körper
EP2062902A4 (fr) Sel de lithium
EP1906944A4 (fr) Preparation de schisandrine b
NO20055643D0 (no) Preparation of lodixanol
PT1763520E (pt) Utilização de benzopiranonas trissubstituídas
DE502007003774D1 (de) Werkzeugaufnahme
EP2013346A4 (fr) Espèces de pestivirus
EP1910272A4 (fr) Inhibiteurs de la renine
ITMI20061048A1 (it) Procedimento per la preparazione di magnesio boroidruro cristallino
FR2877833B1 (fr) Correcteur de lordoses